Pharmaceuticals
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Sept. 23, 2022 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), consisting of three independent directors, Mr.Jian Sun, who is the chairman...
RVAC Medicines Initiates First-in-Human Clinical Trials for mRNA COVID-19 Vaccine Candidates
SINGAPORE, Sept. 21, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company incubated by CBC Group in 2021, announced today that a participant has been dosed in a Phase 1, first-in-human study evaluating the company's mRNA-based COVID-19 vaccine candidat...
Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential
SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of ...
Charsire's New Drug Aims to Capture Multi-Billion-Dollar Dementia Treatment Market
TAINAN CITY, Taiwan, Sept. 21, 2022 /PRNewswire/ -- Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease and vascular dementia using its patented technology of Multi-Glycan Complex and soybeans as raw materials. BAC has completed Phase II ...
MGC Pharmaceuticals Successfully Developed Herbal-inspired Products for Treatment of Long COVID and COVID-19
LONDON, Sept. 21, 2022 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), is a European based bio-pharma company, focused on developing and supplying affordable (Accessible) and Ethically Produced Plant Inspired Medicines, is helping to solve the mystery of treating Lo...
Mediaseek's Proprietary Neurofeedback Engine "Alpha Switch" and Its Smartphone Application Mentioned in International Journal
- Engine and App Used in Research Paper on Chronic Low Back Pain Treatment at Pain Center of Chiba University Hospital Published in "Scientific Reports" - TOKYO, Sept. 21, 2022 /PRNewswire/ -- Mediaseek, Inc. (hereinafter referred to as "Mediaseek") based inTokyo is pleased to announce that a res...
Sirnaomics to Present Latest Developments on siRNA Therapeutics for Cancer and GalAhead(TM) Platform Programs at the 2nd Annual Oligonucleotide Therapeutics and Delivery Conference
GAITHERSBURG, Md. and SUZHOU, China, Sept. 20, 2022 /PRNewswire/ -- Sirnaomics
Ltd
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tr...
Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
* Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections inChina * The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and market...
WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA
WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received reg...
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for th...
Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium
SINGAPORE, Sept. 19, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced thatJerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience's Chief Scientific Offic...
Anyong Biotechnology's Locally Sourced 'Santé Silver Perch Essence' Fulfilling Increasing Demand in The APAC Wellness Industry
KAOHSIUNG, Taiwan, Sept. 19, 2022 /PRNewswire/ -- Taiwan-based Anyong Biotechnology, has created a locally-sourced Santé Silver Perch Essence out of ecologically farmed, certified, and traceable silver perch in major markets such asTaiwan, the United States, Singapore, and Malaysia. As consumers'...
MagicTouch SCB receives IDE approval for In-Stent Restenosis indication
TAMPA, Fla., Sept. 19, 2022 /PRNewswire/ -- The US FDA has granted an
Investigational Device Exemption (IDE) approval forMagicTouch
Everest Medicines Appoints Rogers Yongqing Luo as Chief Executive Officer to Lead Next Stage of Company Growth
SHANGHAI, Sept. 19, 2022 /PRNewswire/ -- Everest Medicines
CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®
SINGAPORE, Sept. 17, 2022 /PRNewswire/ -- CellResearch Corporation, a Singapore -based biopharmaceutical company today announced it has successfully closed the first Phase I study in CorLiCyte®, a stem cell therapy derived from umbilical cord lining stem cells, with research partners at theUnivers...
New treatment for rare cancer cholangiocarcinoma approved in Australia
* Available to treat adults with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement * PEMAZYRE® (pemigatinib) is available via a co-pay access program in Australia SINGAPORE, Sept. 15, 2022 /PRNewswire/ -- A NEW targeted therapy to treat a rare bile duct c...
Hexvix®, A Diagnostic Drug of Asieris, is Now Covered by the 2022 Lecheng Global Specialty Drug Insurance
SHANGHAI, Sept. 15, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced today that Hexvix®, a drug used for...
Austar Lifesciences Announces 2022 Interim Results
Benefiting from the Growth in the Business Segment of Liquid and Bioprocess System and the Increased Capability of Comprehensive Integrated Solutions,its Businesses Grew Steadily Revenue Increased by 29.1% to RMB 1,104 million Operation Highlights (RMB'000) For the six months ended 30 June ...
Winmate Stainless Panel PCs and Displays Solution for Food Packaging Automation
Increasing efficiencies in food processing with Winmate's hygienic and easy to clean solutions TAIPEI, Sept. 15, 2022 /PRNewswire/ -- The urgency of the global low-carbon circular economy impacted the food and drinks industry. Pushing the manufacturer to innovate while increasing their productiv...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00With unique features, Hainan TV opened "The World's Specialty" pavilion at the Expo!
[Picked up by 287 media titles]
2024-04-18 21:26China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25Animated Life in Yunnan
[Picked up by 281 media titles]
2024-04-18 14:00